Literature DB >> 2960608

Theoretical and practical aspects of B-cell activation: murine and human systems.

R H Zubler1, C Werner-Favre, L Wen, K Sekita, C Straub.   

Abstract

We have reviewed observations which were made during studies of murine and human B-cell responses in vitro. One currently faces difficulties in drawing any clear schema as to which external signals elicit which responses (activation, proliferation, differentiation) in B cells. However, the most potent antigen-dependent or polyclonal B-cell responses in vitro occur when, in addition to various cytokines, accessory cells, serum etc., the cultures contain either a) intact T-helper cells which enter into cell-to-cell contact with B cells, or b) some B-cell "mitogen" (T-independent antigen). Murine B cells activated with LPS and anti-Ig antibodies represent a model for the study of IL2 receptor expression and function. LPS does not act on human B cells. Certain mutant EL-4 thymoma cells are potent activators of murine and human B cells via a direct cell-to-cell interaction. The majority of human B cells can be induced to proliferate and generate a few hundred antibody-secreting cells each in the presence of such thymoma cells and a mixture of cytokines. From a practical point of view, this observation should be useful in a variety of investigations such as the analysis of the human B-cell specificity repertoire.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960608     DOI: 10.1111/j.1600-065x.1987.tb01181.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  10 in total

Review 1.  The role of interleukin-4 in IgE and IgG subclass formation.

Authors:  H L Spiegelberg
Journal:  Springer Semin Immunopathol       Date:  1990

2.  Frequencies of HIV-reactive B cells in seropositive and seronegative individuals.

Authors:  R H Zubler; L H Perrin; A Doucet; X Zhang; Y P Huang; P A Miescher
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

Review 3.  Normal and atopic IgE responses.

Authors:  R H Zubler; X Zhang; A Tucci; B S Polla; C Werner-Favre
Journal:  Springer Semin Immunopathol       Date:  1993

4.  Efficient generation of monoclonal antibodies from preselected antigen-specific B cells. Efficient immortalization of preselected B cells.

Authors:  P G Steenbakkers; H A Hubers; A W Rijnders
Journal:  Mol Biol Rep       Date:  1994-03       Impact factor: 2.316

5.  IL-4 and transforming growth factor-beta suppress human immunoglobulin secretion in vitro by surface IgD- B cells.

Authors:  C Ninomiya; H L Spiegelberg
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

6.  Are cord blood B cells functionally mature?

Authors:  A Tucci; A Mouzaki; H James; J Y Bonnefoy; R H Zubler
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

7.  CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.

Authors:  J Kwekkeboom; M De Boer; J M Tager; C De Groot
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

8.  Humoral and cell-mediated autoimmune reactions to human acidic ribosomal P2 protein in individuals sensitized to Aspergillus fumigatus P2 protein.

Authors:  C Mayer; U Appenzeller; H Seelbach; G Achatz; H Oberkofler; M Breitenbach; K Blaser; R Crameri
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

9.  Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A.

Authors:  T Defrance; B Vanbervliet; F Brière; I Durand; F Rousset; J Banchereau
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

10.  Cytokine mRNA expression during an in vitro response of human B lymphocytes: kinetics of B cell tumor necrosis factor alpha, interleukin (IL)6, IL-10, and transforming growth factor beta 1 mRNAs.

Authors:  T Matthes; C Werner-Favre; H Tang; X Zhang; V Kindler; R H Zubler
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.